Mineralys Therapeutics sets IPO target at up to $160M


The Main Line biopharmaceutical company stated in documents filed with the SEC that it plans to sell 10 million shares of common stock.

Previous PSI Metals North America expands Pittsburgh HQ office on the Parkway West
Next List Extra: Serving up some facts and figures on Central Florida's largest catering companies